X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs GLENMARK PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA GLENMARK PHARMA DISHMAN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.1 19.7 127.7% View Chart
P/BV x 3.3 3.5 95.2% View Chart
Dividend Yield % 0.7 0.3 193.4%  

Financials

 DISHMAN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
GLENMARK PHARMA
Mar-17
DISHMAN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs374993 37.7%   
Low Rs129729 17.7%   
Sales per share (Unadj.) Rs197.8325.5 60.8%  
Earnings per share (Unadj.) Rs21.239.3 54.0%  
Cash flow per share (Unadj.) Rs34.748.7 71.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 342.2%  
Book value per share (Unadj.) Rs179.9159.2 113.0%  
Shares outstanding (eoy) m80.69282.17 28.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.6 48.1%   
Avg P/E ratio x11.921.9 54.1%  
P/CF ratio (eoy) x7.217.7 41.0%  
Price / Book Value ratio x1.45.4 25.9%  
Dividend payout %9.45.1 185.3%   
Avg Mkt Cap Rs m20,306242,991 8.4%   
No. of employees `0000.813.0 6.4%   
Total wages/salary Rs m5,35516,408 32.6%   
Avg. sales/employee Rs Th19,252.77,083.9 271.8%   
Avg. wages/employee Rs Th6,459.51,265.4 510.5%   
Avg. net profit/employee Rs Th2,064.1855.1 241.4%   
INCOME DATA
Net Sales Rs m15,96191,857 17.4%  
Other income Rs m265374 71.0%   
Total revenues Rs m16,22692,230 17.6%   
Gross profit Rs m4,10320,367 20.1%  
Depreciation Rs m1,0912,644 41.3%   
Interest Rs m9442,373 39.8%   
Profit before tax Rs m2,33415,724 14.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m6243,827 16.3%   
Profit after tax Rs m1,71111,088 15.4%  
Gross profit margin %25.722.2 115.9%  
Effective tax rate %26.724.3 109.8%   
Net profit margin %10.712.1 88.8%  
BALANCE SHEET DATA
Current assets Rs m11,01868,746 16.0%   
Current liabilities Rs m9,51727,027 35.2%   
Net working cap to sales %9.445.4 20.7%  
Current ratio x1.22.5 45.5%  
Inventory Days Days11085 130.0%  
Debtors Days Days3596 36.5%  
Net fixed assets Rs m16,30424,132 67.6%   
Share capital Rs m161282 57.2%   
"Free" reserves Rs m12,90744,643 28.9%   
Net worth Rs m14,51644,925 32.3%   
Long term debt Rs m4,18945,363 9.2%   
Total assets Rs m29,805117,639 25.3%  
Interest coverage x3.57.6 45.5%   
Debt to equity ratio x0.31.0 28.6%  
Sales to assets ratio x0.50.8 68.6%   
Return on assets %8.911.4 77.9%  
Return on equity %11.824.7 47.8%  
Return on capital %17.519.1 91.6%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95256,152 8.8%   
Fx outflow Rs m6978,084 8.6%   
Net fx Rs m4,25548,068 8.9%   
CASH FLOW
From Operations Rs m2,7866,574 42.4%  
From Investments Rs m-1,529-7,124 21.5%  
From Financial Activity Rs m-9415,432 -17.3%  
Net Cashflow Rs m3161,992 15.9%  

Share Holding

Indian Promoters % 61.4 48.3 127.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 12.7 34.4 36.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 56,727 81.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON LTD  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS